The Role of Ophthalmologic Tests and EEG Imaging in Alzheimer's Disease
The Combination of Ophthalmologic Tests and EEG Imaging as a New Biomarker for Alzheimer's Disease
1 other identifier
observational
60
1 country
1
Brief Summary
Alzheimer's disease (AD) is a prevalent, long-term progressive degenerative disorder with great social impact. It is currently thought that, in addition to neurodegeneration, vascular changes also play a role in the pathophysiology of the disease. Meantime, EEG resting state has also demonstrated significant change in patients with AD in neuroscience research area. Thus, the combination of these sensitive biomarkers would lead to a potential new biomarker for detection of AD, which has higher specificity and sensitivity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 13, 2020
CompletedFirst Posted
Study publicly available on registry
February 20, 2020
CompletedStudy Start
First participant enrolled
September 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2023
CompletedApril 1, 2021
March 1, 2021
5 months
January 13, 2020
March 30, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
OCT retinal and choroidal thickness
retinal structural anatomy
2 days
Retinal Photography vascular caliber
use Retinal Photography to detect vascular caliber
2 days
functional connection strength in the brain network
record resting-state EEG, use graph theory to calculate the functional connection strength
7 days
Study Arms (3)
mild cognitive impairment (MCI)
observational
Patients with mild to moderate AD
observational
Normal controls
observational
Interventions
No intervention
Eligibility Criteria
We would recruit three groups of elders. One is the control group without cognitive impairment, one is the aMCI group which is deemed as the pre-stage of AD, and also the AD group.
You may qualify if:
- Clinical diagnosis of Alzheimer's Disease
You may not qualify if:
- neurologic disorders
- psychiatric disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, 510000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jin Yuan, phD
Zhongshan Ophthalmological Center, Sun Yat-sen University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- assistant dean
Study Record Dates
First Submitted
January 13, 2020
First Posted
February 20, 2020
Study Start
September 1, 2022
Primary Completion
February 1, 2023
Study Completion
July 1, 2023
Last Updated
April 1, 2021
Record last verified: 2021-03